Submit a comment

Combined inhibition of DNA Polymerase Theta and ATR targets MYBL2-high triple-negative breast cancer stem cells
Rachel Bayley, Xiaoping Qu, Adrija Chakraborty, Menna Shamma, Ciara Ward, Kinga Koscielniak, Anna Munsey, Suman Ahmed, Amber Stiby, Bohdana-Myroslava Briantseva, Kirendeep Jawanda, Christopher J. Lord, Abeer M. Shaaban, Marco Saponaro, Graeme C. M. Smith, Robert B. Clarke, Clare Davies, Paloma Garcia
Rachel Bayley, Xiaoping Qu, Adrija Chakraborty, Menna Shamma, Ciara Ward, Kinga Koscielniak, Anna Munsey, Suman Ahmed, Amber Stiby, Bohdana-Myroslava Briantseva, Kirendeep Jawanda, Christopher J. Lord, Abeer M. Shaaban, Marco Saponaro, Graeme C. M. Smith, Robert B. Clarke, Clare Davies, Paloma Garcia
View: Text | PDF
Research In-Press Preview Cell biology Genetics Oncology

Combined inhibition of DNA Polymerase Theta and ATR targets MYBL2-high triple-negative breast cancer stem cells

Abstract

Triple negaJve breast cancer (TNBC) is characterised by poor prognosis and limited treatment opJons, parJally due to therapy-resistant stem/progenitor cells driving metastasis. Elevated expression of the transcripJon factor MYBL2 is associated with aggressive disease, yet its role in BC stem/progenitor cells remains elusive. Here, we employed inducible MYBL2 downregulaJon in TNBC cell lines and paJent-derived models to invesJgate its funcJon and idenJfy potenJal vulnerabiliJes associated with its high expression. Our funcJonal and mechanisJc analyses reveal that high MYBL2 levels are criJcal for stem cell self-renewal, DNA repair, and replicaJon stress response and lowering MYBL2 impairs stemness and self-renewal both in vitro and in vivo. Accordingly, high-MYBL2 stem/progenitor cells exhibit increased sensiJvity to Polθ inhibitors which is lost upon MYBL2 downregulaJon due to transcripJonal suppression. Combining Polθ inhibitors with ATR inhibitors further enhances this sensiJvity, in vitro, ex vivo and in vivo. These findings suggest that dual Polθ/ATR inhibiJon represents a promising therapeuJc strategy to target TNBC stem/progenitor cells with high MYBL2 expression, highlighJng MYBL2 as a potenJal biomarker to straJfy paJents for Polθ inhibitor-based therapies in TNBC.

Authors

Rachel Bayley, Xiaoping Qu, Adrija Chakraborty, Menna Shamma, Ciara Ward, Kinga Koscielniak, Anna Munsey, Suman Ahmed, Amber Stiby, Bohdana-Myroslava Briantseva, Kirendeep Jawanda, Christopher J. Lord, Abeer M. Shaaban, Marco Saponaro, Graeme C. M. Smith, Robert B. Clarke, Clare Davies, Paloma Garcia

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required